CALA News and Press, Calithera Biosciences Inc. From 06/18/19

Digital Ally (NASDAQ: DGLY )  -42%  on Axon patent win. More news on: Digital Ally, Inc., ContraVir Pharmaceuticals, Inc., Biohaven Pharmaceutical Holding Company Ltd., Stocks on the move, Read more ...

Gainers: MGI   +117.9% . PHAS   +14.0% . NSPR   +7.4% . EIGR   +4.9% . ARQL   +2.7% . More news on: MoneyGram International, Inc., PhaseBio Pharmaceuticals, Inc., InspireMD, Inc., Stocks on the move, , News on ETFs Read more ...

Calithera Biosciences (NASDAQ: CALA ) announces secondary offering of 10M shares More news on: Calithera Biosciences, Inc., Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Gainers:  Sotheby's (NYSE: BID ) +58% . Array BioPharma (NASDAQ: ARRY ) +57% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +42% . Vislink Technologies (NASDAQ: VISL ) +40% . MTech Acquisition (NASDAQ: MTEC ) +34% . Endurance International Group Holdings (NASDAQ: EIGI ) +26% . C&am...

Calithera Biosciences (NASDAQ: CALA ) reports positive results from its Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). More news on: Calithera Biosciences, Inc., Healthcare stocks news, Stocks on the mo...

-Doubled median progression-free survival (PFS) in heavily pre-treated patients with advanced renal cell carcinoma -Provides first clinical proof of concept for glutaminase inhibitor telaglenastat -Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT...

NetworkNewsWire Editorial Coverage : Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is leveraging its patented technology pla...

Calithera Biosciences, Inc. (CALA) Q1 2019 Results Earnings Conference Call May 09, 2019, 5:00 pm ET Company Participants Jennifer McNealey - Vice President of Investor Relations and Strategy Susan Molineaux - Founder, President, Chief Executive Officer Keith Orford - Chief Medic...

Calithera Biosciences (NASDAQ: CALA ): Q1 GAAP EPS of -$0.61 misses by $0.18 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...